Day: November 11, 2021

Vinci Partners Impact and Return Strategy Announces Investment in Verdfrut

Vinci Partners Impact and Return Strategy Announces Investment in Verdfrut

RIO DE JANEIRO, Brazil, Nov. 11, 2021 (GLOBE NEWSWIRE) — Vinci Partners Investments Ltd. (NASDAQ: VINP) (“Vinci Partners”, “we”, “us” or “our”), the controlling company of a leading alternative investment platform in Brazil, announced today that “Vinci Impacto e Retorno IV”, or “VIR IV” (“the Fund”), the Impact family of funds managed by Vinci Partners’ Private Equity strategy, closed an acquisition equivalent to a 34.0% stake in Verdfrut (“the Company”), a Brazilian SME Fruits & Vegetables (F&V) retailer and B2B Distribution operation (DC). VIR IV has a unique strategy in Brazil, with a dual mandate to generate favorable market returns as well as impact, through the acquisition of minority holdings in small-and-medium sized Brazilian enterprises, that exhibit growth potential and clear measurable environmental, social...

Continue reading

IBEX Reports Results for the Year Ended July 31, 2021

IBEX Reports Results for the Year Ended July 31, 2021

MONTRÉAL, Québec, Nov. 11, 2021 (GLOBE NEWSWIRE) — IBEX Technologies Inc. (“IBEX” or the “Company”) (TSX Venture: IBT) today reported its financial results for the fiscal year ended July 31, 2021. “IBEX had another very good year, with EBITDA reaching a record level”, said Mr. Baehr, IBEX President & CEO. “The strong financial performance resulted from near-record revenues and a reduction in expenses, due mainly to the closure of the Iowa production facility. The increase in revenues was driven by strong sales of heparinase-based products.” He further stated: “We were particularly pleased by the strong fourth quarter sales which may be an indicator of a return to more normal purchasing patterns by our customers in the hemostasis diagnostics market segment.” Note: All figures are in Canadian dollars unless otherwise stated....

Continue reading

Firm Capital Property Trust Announces Strong Third Quarter Results, Ninth Distribution Increase in Nine Years and $8.21/Unit NAV

Firm Capital Property Trust Announces Strong Third Quarter Results, Ninth Distribution Increase in Nine Years and $8.21/Unit NAV

+2% Increase in Monthly Distributions Commencing in 2022 +8% NAV Growth since the Beginning of 2021 $28 Million of YTD Capital Recycling $124 Million in YTD Acquisitions TORONTO, Nov. 11, 2021 (GLOBE NEWSWIRE) — Firm Capital Property Trust (“FCPT” or the “Trust”), (TSXV: FCD.UN) is pleased to report its financial results for the period ended September 30, 2021, a 2% distribution increase (48.6% cumulative distribution increases in nine years or since inception) and 8% NAV growth since the beginning of 2021: TENANT DIVERSIFICATION The portfolio is well diversified by tenant profile with no tenant currently accounting for more than 11.7% of total net rent. Further, the top 10 tenants are comprised of large national tenants and account for 30.7% of total net rent. PROPERTY PORTFOLIO HIGHLIGHTS The portfolio consists of 62 commercial...

Continue reading

Fancamp Announces Grant of Stock Options

Fancamp Announces Grant of Stock Options

VANCOUVER, British Columbia, Nov. 11, 2021 (GLOBE NEWSWIRE) — Fancamp Exploration Ltd. (“Fancamp” or the “Corporation”) (TSX Venture Exchange: FNC) announced that it has granted options to acquire a total of 13,000,000 common shares of the Corporation to officers, directors, and consultants, pursuant to the Corporation’s Stock Option Plan, at the exercise price of $0.12 per share for a period of five years. The options are granted pursuant to the Corporation’s Stock Option Plan, under which a maximum of ten percent (10%) of the issued and outstanding common shares are reserved for issuance.  About Fancamp Exploration Ltd. (TSX-V: FNC) Fancamp is a growing Canadian mineral exploration corporation dedicated to its value-added strategy of advancing mineral properties through exploration and development. The Corporation owns...

Continue reading

Rapid Micro Biosystems Reports Third Quarter 2021 Financial Results

Rapid Micro Biosystems Reports Third Quarter 2021 Financial Results

Reports third quarter 2021 total revenue of $6.9 million and commercial revenue of $6.3 million Reaffirms full-year 2021 commercial revenue outlook of at least $24.0 million, representing at least 70% year-over-year growth LOWELL, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) — Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced its financial results for the third quarter ended September 30, 2021. Financial Highlights and Business Update Recorded commercial revenue of $6.3 million for the third quarter of 2021, representing 27% year-over-year growth. Generated recurring commercial revenue of $2.2 million, representing 154% year-over-year...

Continue reading

MediciNova Announces MN-001 (tipelukast) Data regarding Lipid Metabolism in NASH/NAFLD to be Presented at The Liver Meeting® 2021, the Annual Meeting of the American Association for the Study of Liver Diseases

MediciNova Announces MN-001 (tipelukast) Data regarding Lipid Metabolism in NASH/NAFLD to be Presented at The Liver Meeting® 2021, the Annual Meeting of the American Association for the Study of Liver Diseases

LA JOLLA, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova’s research collaborator Masatsune Ogura, M.D., Ph.D., Associate Professor at the Department of General Medical Science, Chiba University Graduate School of Medicine, is presenting results and findings of a study that investigated the mechanism by which MN-001 (tipelukast) alters triglyceride (TG) metabolism in hepatocytes at The Liver Meeting® 2021, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) to be held online from November 12th to 15th. In this study, HepG2 cells derived from human hepatocellular carcinoma samples were incubated for 48 hours...

Continue reading

<div>INTRUSION Appoints Renowned Cybersecurity Expert, Tony Scott, as New President & CEO</div>

INTRUSION Appoints Renowned Cybersecurity Expert, Tony Scott, as New President & CEO

Brings Extensive Experience as Former Federal CIO for U.S. Government as well as Fortune 100 Companies PLANO, Texas, Nov. 11, 2021 (GLOBE NEWSWIRE) — INTRUSION (Nasdaq: INTZ), a leader in cyberattack prevention solutions including zero-days, today appointed Tony Scott as its new President and CEO, who will assume the role on Monday, November 15, 2021. Scott brings to INTRUSION many years of executive leadership and cybersecurity experience, including serving as Federal CIO for the U.S. government, CIO for multi-billion corporations such as VMware, Microsoft and The Walt Disney Company, as well as a private consultant helping organizations implement effective world class solutions for cybersecurity, IT governance and crisis management. Prior to his appointment, Scott had been serving as the founder and CEO of the TonyScottGroup,...

Continue reading

Adaptive Biotechnologies Receives Updated Medicare Coverage for its Minimal Residual Disease (MRD) Assay, clonoSEQ® for Blood Cancer Patients

Adaptive Biotechnologies Receives Updated Medicare Coverage for its Minimal Residual Disease (MRD) Assay, clonoSEQ® for Blood Cancer Patients

Local coverage determination (LCD) confirms access to the only FDA-cleared in vitro diagnostic to detect and monitor minimal residual disease (MRD) from bone marrow and blood sample types in certain blood cancers LCD supports the expansion of coverage for additional clonoSEQ indications, providing a clear pathway for Non-Hodgkin’s Lymphoma (NHL) and other lymphoid cancers SEATTLE, Nov. 11, 2021 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced that Palmetto GBA’s Molecular Diagnostics Program (MolDX) has finalized a local coverage determination (LCD) which supports the Medicare coverage for clonoSEQ® to detect and monitor minimal residual...

Continue reading

Contango Announces Schedule for Third Quarter 2021 Earnings Release

Contango Announces Schedule for Third Quarter 2021 Earnings Release

FORT WORTH, Texas, Nov. 11, 2021 (GLOBE NEWSWIRE) — Contango Oil & Gas Company (NYSE American: MCF) (“Contango” or the “Company”) announced today that it plans to issue its third quarter 2021 earnings release after market close on Monday, November 15, 2021. Teleconference Call In light of the previously announced Special Meeting of Shareholders of Contango scheduled to be held on December 6, 2021, whereby Contango shareholders will vote on the Proposed Merger with Independence Energy, LLC, the Company will not host a conference call to discuss the contents of the third quarter earnings release. We expect to include in the earnings release sufficient information to allow interested parties to fully understand financial and operational results for the quarter. About Contango Oil & Gas Company Contango Oil & Gas Company is...

Continue reading

Nova Leap Health Corp. Announces Execution of Definitive Agreement

Nova Leap Health Corp. Announces Execution of Definitive Agreement

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX, Nova Scotia, Nov. 11, 2021 (GLOBE NEWSWIRE) — NOVA LEAP HEALTH CORP. (TSXV: NLH) (“Nova Leap” or “the Company”), a growing home health care organization, is pleased to announce that it has executed a definitive agreement (the “Agreement”), dated November 11, 2021, to acquire a home care services company (“the Target”) with operations in the Southern and Midwestern regions of the U.S. The Target reported unaudited annualized 2021 year-to-date revenues of approximately $4.1 million and EBITDA of $825,000. All amounts are in United States Dollars (“USD”) unless otherwise specified. Under the terms of the Agreement, the acquisition is to be made for total consideration of $4.75 million of which $4.4 million is payable with cash on closing...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.